EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

Chenyang Jiang, Hao Sun, Zhongxing Jiang, Wenzhi Tian, Shundong Cang, Jifeng Yu

Frontiers in Oncology · 05.07.2024 · 14

DOI: 10.3389/fonc.2024.1378647 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 05.07.2024. Verfasst von Chenyang Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since its initial report in 2015, CD47 has garnered significant attention as an innate immune checkpoint, raising expectations to become the next “PD-1.” The optimistic early stages of clinical development spurred a flurry of licensing deals for CD47-targeted molecules and company mergers or acquisitions for related assets. However, a series of setbacks unfolded recently, starting with the July 2023 announcement of discontinuing the phase 3 ENHANCE study on Magrolimab plus Azacitidine for higher-risk myelodysplastic syndromes (MDS). Subsequently, in August 2023, the termination of the ASPEN-02 program, assessing Evorpacept in combination with Azacitidine in MDS patients, was disclosed due to insufficient improvement compared to Azacitidine alone. These setbacks have cast doubt on the feasibility of targeting CD47 in the industry. In this review, we delve into the challenges of developing CD47-SIRPα-targeted drugs, analyze factors contributing to the mentioned setbacks, discuss future perspectives, and explore potential solutions for enhancing CD47-SIRPα-targeted drug development.

Schlagwörter

Stichwörter der Autor:innen

SIRPαcancer immunotherapycd47monoclonal antibodysignaling pathwaytargeted therapy

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Oncology, Henan Key Laboratory for Precision Medicine in Cancer, Henan Provincial People's Hospital, Henan University People's Hospital and Zhengzhou University, Zhengzhou, Henan, China.
  • Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China.

Zitieren

APA

Jiang, C., Sun, H., Jiang, Z., Tian, W., Cang, S., & Yu, J. (2024). Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1378647

Vancouver

Jiang C, Sun H, Jiang Z, Tian W, Cang S, Yu J. Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1378647

BibTeX
@article{Jiang2024,
  author = {Jiang, Chenyang and Sun, Hao and Jiang, Zhongxing and Tian, Wenzhi and Cang, Shundong and Yu, Jifeng},
  title = {Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1378647}
}
Kostenlos starten →